Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):393-406. doi: 10.1586/erp.13.19. Epub 2013 Mar 28.

PMID:
23537397
2.

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

Hum Vaccin. 2008 May-Jun;4(3):238-45. Epub 2010 May 25.

PMID:
18382137
3.

A systematic review of the cost effectiveness of herpes zoster vaccination.

Szucs TD, Pfeil AM.

Pharmacoeconomics. 2013 Feb;31(2):125-36. doi: 10.1007/s40273-012-0020-7. Review.

PMID:
23335045
4.

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Pellissier JM, Brisson M, Levin MJ.

Vaccine. 2007 Nov 28;25(49):8326-37. Epub 2007 Oct 17.

PMID:
17980938
5.

Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.

BMC Health Serv Res. 2013 Sep 26;13:359. doi: 10.1186/1472-6963-13-359.

6.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Rothberg MB, Virapongse A, Smith KJ.

Clin Infect Dis. 2007 May 15;44(10):1280-8. Epub 2007 Apr 3.

PMID:
17443464
7.

Cost effectiveness of herpes zoster vaccine in Canada.

Najafzadeh M, Marra CA, Galanis E, Patrick DM.

Pharmacoeconomics. 2009;27(12):991-1004. doi: 10.2165/11314010-000000000-00000.

PMID:
19908924
8.

Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.

Annemans L, Bresse X, Gobbo C, Papageorgiou M.

J Med Econ. 2010;13(3):537-51. doi: 10.3111/13696998.2010.502854.

PMID:
20707768
9.

Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.

Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ.

Vaccine. 2014 Mar 26;32(15):1645-53. doi: 10.1016/j.vaccine.2014.01.058. Epub 2014 Feb 15. Review.

PMID:
24534737
10.

Cost-effectiveness of vaccination against herpes zoster.

de Boer PT, Wilschut JC, Postma MJ.

Hum Vaccin Immunother. 2014;10(7):2048-61. doi: 10.4161/hv.28670. Review.

11.

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.

de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ.

Vaccine. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067. Epub 2013 Jan 8.

PMID:
23306360
12.

COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.

Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A.

Int J Technol Assess Health Care. 2016 Jan;32(4):233-240. Epub 2016 Sep 14.

PMID:
27624398
13.

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Hornberger J, Robertus K.

Ann Intern Med. 2006 Sep 5;145(5):317-25.

PMID:
16954357
14.

Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.

Le P, Rothberg MB.

Ann Intern Med. 2015 Oct 6;163(7):489-97. doi: 10.7326/M15-0093.

PMID:
26344036
15.

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X.

Hum Vaccin. 2011 Jul;7(7):749-56. doi: 10.4161/hv.7.7.15573. Epub 2011 Jul 1.

16.

Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.

Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N.

Hum Vaccin Immunother. 2015;11(4):884-96. doi: 10.1080/21645515.2015.1011561.

17.

The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.

Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M.

J Med Econ. 2016 Jun;19(6):576-86. doi: 10.3111/13696998.2016.1146726. Epub 2016 Mar 2.

PMID:
26808422
18.

Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.

Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P.

Vaccine. 2012 Jan 11;30(3):675-84. doi: 10.1016/j.vaccine.2011.10.036. Epub 2011 Nov 24.

PMID:
22120193
19.

Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia.

Brisson M, Pellissier JM, Levin MJ.

Clin Infect Dis. 2007 Dec 1;45(11):1527-9. No abstract available.

PMID:
17990240
20.

Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.

Graham J, Mauskopf J, Kawai K, Johnson KD, Xu R, Acosta CJ.

J Manag Care Spec Pharm. 2016 Jul;22(7):872-88. doi: 10.18553/jmcp.2016.22.7.872.

Supplemental Content

Support Center